查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非囊性纤维化支气管扩张市场：全球市场规模、份额、趋势分析、机会、预测报告，2019-2029
市场调查报告书
商品编码
1334470

非囊性纤维化支气管扩张市场：全球市场规模、份额、趋势分析、机会、预测报告，2019-2029

Non-cystic Fibrosis Bronchiectasis Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Treatment ; By Type ; By Diagnosis ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到2029年，全球非囊性纤维化支气管扩张市场规模将达到13亿美元。

全球非囊性纤维化支气管扩张症市场的推动因素包括非囊性纤维化支气管扩张症患病率上升、全球人口快速高龄化和呼吸系统疾病的高易感性以及诊断技术的不断进步。由于技术的进步，该疾病正在蓬勃发展。 ，提高认识和早期诊断工作。

领先的战略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，到 2022 年，非囊性纤维化支气管扩张症的全球市场规模将达到 9.4 亿美元。 BlueWeave表示，在2023-2029年的预测期内，全球非囊性纤维化支气管扩张症市场规模预计将以5.55%的年复合成长率增长，并于2029年达到12.98亿美元。全球非囊性纤维化支气管扩张市场的主要成长促进因素包括慢性病患病率的增加、医疗保健支出的增加以及政府倡议的增加。治疗方案的进步以及公众和医疗保健专业人员对支气管扩张症状认识的提高，导致了早期诊断和患者管理的改善。市场增长也受到医疗保健支出增加的显着影响，特别是在新兴经济体，这正在改善支气管扩张患者获得诊断和治疗的机会。不断增加的研发活动和新兴市场提供的潜在机会预计将在预测期内进一步推动市场开拓。然而，治疗选择有限、缺乏针对特异性疾病的治疗、疾病管理和患者依从性方面的课题、高昂的治疗成本和医疗保健负担预计将限制分析期间的整体市场增长。

该报告的详细分析提供了有关全球非囊性纤维化支气管扩张市场的增长潜力、未来趋势和统计数据的资讯。它还涵盖了推动市场总规模预测的要素。该报告承诺提供全球非囊性纤维化支气管扩张市场的最新技术趋势以及行业见解，以帮助决策者做出明智的战略决策。此外，我们还分析了市场的成长促进因素、课题和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球非囊性纤维化支气管扩张市场洞察

  • 行业价值链分析
  • DROC分析
    • 增长动力
      • 非囊性纤维化支气管扩张的患病率增加
      • 人口高龄化，呼吸道疾病高罹患率
      • 诊断技术的进步
      • 努力提高认识和早期诊断
    • 抑制因素
      • 治疗选择有限且缺乏针对疾病的特异性治疗
      • 疾病管理和患者依从性方面的课题
      • 高昂的治疗费用和医疗负担
    • 机会
      • 对个人化医疗和精准治疗方法的需求不断增长
      • 医疗保健成本上升和基础设施发展
    • 课题
      • 复杂疾病的病理学和异质性
      • 临床管理指南缺乏共识
  • 技术进步/最新发展
  • 法律规范
  • 波特五力分析

第4章全球非囊性纤维化支气管扩张市场概述

  • 2019-2029 年市场规模和金额预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
      • 外科手术
      • 物理疗法
      • 疫苗接种
      • 气道药物
      • 抗生素
      • 其他的
    • 按类型
      • 静脉
      • 口服
      • 其他的
    • 通过诊断
      • CT扫描
      • 支气管镜检查
      • 胸部X光检查
      • 肺功能
      • 痰培养测试
      • 验血
      • 其他的
    • 按最终用户
      • 诊所
      • 医院
      • 其他的
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第5章北美非囊性纤维化支气管扩张市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按类型
    • 通过诊断
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第6章欧洲非囊性纤维化支气管扩张市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按类型
    • 通过诊断
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 荷兰
      • 其他欧洲国家

第7章亚太非囊性纤维化支气管扩张市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按类型
    • 通过诊断
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 菲律宾
      • 越南
      • 亚太地区其他国家

第8章拉丁美洲非囊性纤维化支气管扩张市场

  • 2019-2029 年市场规模和价值预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按类型
    • 通过诊断
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 哥伦比亚
      • 拉丁美洲其他地区

第9章中东和非洲非囊性纤维化支气管扩张市场

  • 2019-2029 年市场规模和金额预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按类型
    • 通过诊断
    • 按最终用户
    • 按国家/地区
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • MEA 的其余部分

第10章竞争形势

  • 主要企业及其产品列表
  • 2022 年全球非囊性纤维化支气管扩张公司市场份额分析
  • 通过管理参数进行竞争基准测试
  • 主要战略发展（合併、收购、合作伙伴关係等）

第11章COVID-19 对全球非囊性纤维化支气管扩张市场的影响

第12章公司简介（公司简介、财务矩阵、竞争形势、关键人才、主要竞争、联繫地址、战略展望和SWOT分析）

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • Insmed Incorporated
  • Bayer AG
  • Other Prominent Players

第13章关键战略建议

第14章调查方法

简介目录
Product Code: BWC23655

Global Non-cystic Fibrosis Bronchiectasis Market Size Set to Touch USD 1.3 Billion by 2029.

Global non-cystic fibrosis bronchiectasis market is flourishing because of the rising prevalence of non-cystic fibrosis bronchiectasis, rapidly aging world population and its higher susceptibility to respiratory diseases, ongoing advancements in diagnostic technologies, and growing awareness and early diagnosis initiatives.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global non-cystic fibrosis bronchiectasis market size at USD 0.94 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global non-cystic fibrosis bronchiectasis market size to grow at a CAGR of 5.55% reaching a value of USD 1.298 billion by 2029. Major growth drivers for the global non-cystic fibrosis bronchiectasis market include an increasing prevalence of chronic diseases, coupled with a rising healthcare expenditure and growing government initiatives. Advancements in treatment options and growing awareness among the general population and healthcare professionals about bronchiectasis symptoms have led to early diagnosis and improved patient management. Also, the market's growth is notably influenced by rising healthcare spending, particularly in emerging economies, which has facilitated better access to diagnosis and treatment for bronchiectasis patients. The rise in research and development activities and the potential opportunities presented by emerging markets are expected to further propel the market's development during the forecast period. However, limited treatment options and lack of disease-specific therapies, challenges in disease management and patient adherence, and the high cost of treatment and healthcare burden are anticipated to restrain the overall market growth during the period in analysis.

Global Non-cystic Fibrosis Bronchiectasis Market - Overview:

The global non-cystic fibrosis bronchiectasis market refers to the worldwide industry involved in the diagnosis, treatment, and management of non-cystic fibrosis bronchiectasis, a chronic respiratory condition. Bronchiectasis is characterized by permanent dilation of the bronchi, leading to recurrent respiratory infections and impaired lung function. Unlike cystic fibrosis-related bronchiectasis, non-cystic fibrosis bronchiectasis is not caused by the genetic disorder cystic fibrosis. The market encompasses various healthcare stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions, all contributing to the development of innovative therapies, medications, and diagnostic tools to address the challenges posed by non-cystic fibrosis bronchiectasis and improve patients' quality of life.

Impact of COVID-19 on Global Non-cystic Fibrosis Bronchiectasis Market:

COVID-19 pandemic adversely affected the global non-cystic fibrosis bronchiectasis market. During the pandemic, healthcare systems were overwhelmed with managing COVID-19 patients, leading to a reduced focus on non-emergency conditions like bronchiectasis. Patients with respiratory conditions faced challenges in accessing healthcare facilities and adhering to treatment regimens due to restrictions and safety concerns. Also, disruptions in the supply chain and clinical trials affected the availability of treatments and research activities. However, with the gradual containment of the pandemic, the market is expected to recover as healthcare systems restore non-emergency services, and efforts to improve respiratory care continue.

Global Non-cystic Fibrosis Bronchiectasis Market - By End User:

On the basis of end user, the global non-cystic fibrosis bronchiectasis market is bifurcated into Clinic and Hospital segments. The hospital segment held a higher market share by end-users. Hospitals are major healthcare centers where patients with respiratory conditions like non-cystic fibrosis bronchiectasis often seek diagnosis, treatment, and management. Hospitals typically have advanced medical facilities, equipment, and specialized healthcare professionals, making them capable of providing comprehensive care for bronchiectasis patients. Also, non-cystic fibrosis bronchiectasis may require specialized diagnostic tests and treatments, such as CT scans, bronchoscopies, and lung function tests, which are readily available in hospitals. The hospital setting also allows for closer monitoring of patients and immediate intervention in case of complications.

Competitive Landscape:

Major players operating in the global non-cystic fibrosis bronchiectasis market include: Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals Inc., Insmed Incorporated, and Bayer AG. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-cystic Fibrosis Bronchiectasis Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Non-cystic Fibrosis Bronchiectasis Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Non-cystic Fibrosis Bronchiectasis Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Prevalence of Non-Cystic Fibrosis Bronchiectasis
      • 3.2.1.2. Aging Population and Higher Susceptibility to Respiratory Diseases
      • 3.2.1.3. Advancements in Diagnostic Technologies
      • 3.2.1.4. Growing Awareness and Early Diagnosis Initiatives
    • 3.2.2. Restraints
      • 3.2.2.1. Limited Treatment Options and Lack of Disease-Specific Therapies
      • 3.2.2.2. Challenges in Disease Management and Patient Adherence
      • 3.2.2.3. High Cost of Treatment and Healthcare Burden
    • 3.2.3. Opportunities
      • 3.2.3.1. Rising Demand for Personalized Medicine and Precision Treatment Approaches
      • 3.2.3.2. Increasing Healthcare Expenditure and Infrastructure Development
    • 3.2.4. Challenges
      • 3.2.4.1. Complex Disease Pathophysiology and Heterogeneity
      • 3.2.4.2. Lack of Consensus on Clinical Management Guidelines
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Non-cystic Fibrosis Bronchiectasis Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment
      • 4.2.1.1. Surgery
      • 4.2.1.2. Physiotherapy
      • 4.2.1.3. Vaccination
      • 4.2.1.4. Airway Pharmacotherapy
      • 4.2.1.5. Antibiotics
      • 4.2.1.6. Others
    • 4.2.2. By Type
      • 4.2.2.1. Intravenous
      • 4.2.2.2. Oral
      • 4.2.2.3. Others
    • 4.2.3. By Diagnosis
      • 4.2.3.1. CT scan
      • 4.2.3.2. Bronchoscopy
      • 4.2.3.3. Chest X-Ray
      • 4.2.3.4. Lung Function
      • 4.2.3.5. Sputum Culture Test
      • 4.2.3.6. Blood Tests
      • 4.2.3.7. Others
    • 4.2.4. By End User
      • 4.2.4.1. Clinic
      • 4.2.4.2. Hospital
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Non-cystic Fibrosis Bronchiectasis Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment
    • 5.2.2. By Type
    • 5.2.3. By Diagnosis
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Treatment
      • 5.2.5.1.2. By Type
      • 5.2.5.1.3. By Diagnosis
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Treatment
      • 5.2.5.2.2. By Type
      • 5.2.5.2.3. By Diagnosis
      • 5.2.5.2.4. By End User

6. Europe Non-cystic Fibrosis Bronchiectasis Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Type
    • 6.2.3. By Diagnosis
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Treatment
      • 6.2.5.1.2. By Type
      • 6.2.5.1.3. By Diagnosis
      • 6.2.5.1.4. By End User
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Treatment
      • 6.2.5.2.2. By Type
      • 6.2.5.2.3. By Diagnosis
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Treatment
      • 6.2.5.3.2. By Type
      • 6.2.5.3.3. By Diagnosis
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Treatment
      • 6.2.5.4.2. By Type
      • 6.2.5.4.3. By Diagnosis
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Treatment
      • 6.2.5.5.2. By Type
      • 6.2.5.5.3. By Diagnosis
      • 6.2.5.5.4. By End User
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Treatment
      • 6.2.5.6.2. By Type
      • 6.2.5.6.3. By Diagnosis
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Treatment
      • 6.2.5.7.2. By Type
      • 6.2.5.7.3. By Diagnosis
      • 6.2.5.7.4. By End User

7. Asia-Pacific Non-cystic Fibrosis Bronchiectasis Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Type
    • 7.2.3. By Diagnosis
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Treatment
      • 7.2.5.1.2. By Type
      • 7.2.5.1.3. By Diagnosis
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Treatment
      • 7.2.5.2.2. By Type
      • 7.2.5.2.3. By Diagnosis
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Treatment
      • 7.2.5.3.2. By Type
      • 7.2.5.3.3. By Diagnosis
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Treatment
      • 7.2.5.4.2. By Type
      • 7.2.5.4.3. By Diagnosis
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Treatment
      • 7.2.5.5.2. By Type
      • 7.2.5.5.3. By Diagnosis
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Treatment
      • 7.2.5.6.2. By Type
      • 7.2.5.6.3. By Diagnosis
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Treatment
      • 7.2.5.7.2. By Type
      • 7.2.5.7.3. By Diagnosis
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Treatment
      • 7.2.5.8.2. By Type
      • 7.2.5.8.3. By Diagnosis
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Treatment
      • 7.2.5.9.2. By Type
      • 7.2.5.9.3. By Diagnosis
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Treatment
      • 7.2.5.10.2. By Type
      • 7.2.5.10.3. By Diagnosis
      • 7.2.5.10.4. By End User
      • 7.2.5.11. Rest of APAC
      • 7.2.5.11.1. By Treatment
      • 7.2.5.11.2. By Type
      • 7.2.5.11.3. By Diagnosis
      • 7.2.5.11.4. By End User

8. Latin America Non-cystic Fibrosis Bronchiectasis Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Type
    • 8.2.3. By Diagnosis
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Treatment
      • 8.2.5.1.2. By Type
      • 8.2.5.1.3. By Diagnosis
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Treatment
      • 8.2.5.2.2. By Type
      • 8.2.5.2.3. By Diagnosis
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Treatment
      • 8.2.5.3.2. By Type
      • 8.2.5.3.3. By Diagnosis
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Treatment
      • 8.2.5.4.2. By Type
      • 8.2.5.4.3. By Diagnosis
      • 8.2.5.4.4. By End User
      • 8.2.5.4.5.
      • 8.2.5.5. Colombia
      • 8.2.5.5.1. By Treatment
      • 8.2.5.5.2. By Type
      • 8.2.5.5.3. By Diagnosis
      • 8.2.5.5.4. By End User
      • 8.2.5.6. Rest of LATAM
      • 8.2.5.6.1. By Treatment
      • 8.2.5.6.2. By Type
      • 8.2.5.6.3. By Diagnosis
      • 8.2.5.6.4. By End User

9. Middle East & Africa Non-cystic Fibrosis Bronchiectasis Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Type
    • 9.2.3. By Diagnosis
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Treatment
      • 9.2.5.1.2. By Type
      • 9.2.5.1.3. By Diagnosis
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Treatment
      • 9.2.5.2.2. By Type
      • 9.2.5.2.3. By Diagnosis
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Treatment
      • 9.2.5.3.2. By Type
      • 9.2.5.3.3. By Diagnosis
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Treatment
      • 9.2.5.4.2. By Type
      • 9.2.5.4.3. By Diagnosis
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Treatment
      • 9.2.5.5.2. By Type
      • 9.2.5.5.3. By Diagnosis
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Treatment
      • 9.2.5.6.2. By Type
      • 9.2.5.6.3. By Diagnosis
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Treatment
      • 9.2.5.7.2. By Type
      • 9.2.5.7.3. By Diagnosis
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Treatment
      • 9.2.5.8.2. By Type
      • 9.2.5.8.3. By Diagnosis
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Non-cystic Fibrosis Bronchiectasis Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Non-cystic Fibrosis Bronchiectasis Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

  • 12.1. Novartis AG
  • 12.2. Teva Pharmaceutical Industries Ltd.
  • 12.3. Mylan N.V.
  • 12.4. Pfizer Inc.
  • 12.5. GlaxoSmithKline plc
  • 12.6. AstraZeneca plc
  • 12.7. Boehringer Ingelheim GmbH
  • 12.8. Sunovion Pharmaceuticals Inc.
  • 12.9. Insmed Incorporated
  • 12.10. Bayer AG
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumption & Limitation